ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1655

HLA-B27 and KIR3DL2 Interactions Promote The Differentiation and Survival Of Proinflammatory T Cells In Spondyloarthritis

A. Ridley1, I. Wong-Baeza2, H. Hatano2, J. Shaw2, H. Al-Mossawi2, P. Bowness2 and S. Kollnberger2, 1Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom, 2Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: KIR (Killer Ig like receptor), T cells and spondylarthritis

  • Tweet
  • Email
  • Print
Session Information

Title: T-cell Biology in Autoimmune Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose: T helper 17 (Th17) cells are a subset of pro-inflammatory CD4+ T cells implicated in a number of inflammatory arthritides including the Spondyloarthritides (SpAs).  Ankylosing Spondylitis (AS), the commonest spondyloarthropathy, is genetically associated with HLA-B27 (B27) and IL-23 receptor polymorphisms, however the link remains unexplained.  We have previously shown KIR3DL2+ CD4+ T cells are expanded in the peripheral blood of individuals with AS. In addition to classically folded heterotrimers, HLA-B27 can form β2m-free homodimers (B272). B272, as well as free heavy chains, are able to interact with KIR3DL2. The aim of this study was to investigate whether KIR3DL2 expression was induced by activation of CD4+ T cells and to investigate the consequence of co-culturing HLA-B272-expressing cells with KIR3DL2+ CD4+ T cells.

Methods: Production of cytokines by PMA/ionomycin stimulated-peripheral blood mononuclear cells (PBMCs) was investigated by intracellular cytokine staining (ICS). KIR3DL2 expression by PMA/ionomycin stimulated-naïve CD4+ T cells was investigated by flow cytometry (FACS).  Expression of Bcl-2, RORC and T-bet by naïve CD4+ T cells was investigated using qPCR after co-culture with SEB stimulated-HLA-B272-expressing cells, or control HLA-expressing cells.

Results: KIR3DL2+ CD4+ T cells from AS patients are enriched for production of IL-17 (p<0.0001, n=16) and IL-17/IFNγ (p=0.002, n=8), as compared to KIR3DL2- CD4+ T cells. KIR3DL2+ CD4+ T cells from AS patients produce more IL-17 than KIR3DL2+ CD4+ T cells from HLA-B27- healthy controls (p=0.013). Naïve CD4+ T cells express KIR3DL2 de novo by FACS after activation (p=0.02, n=3). Co-culture of naïve CD4+ T cells with HLA-B272-expressing cells further increased KIR3DL2 expression and increased expression of the anti-apoptotic molecule Bcl-2.  Time-dependant alterations in RORC and T-bet expression were observed.

Conclusion: Expression of KIR3DL2 on naïve CD4+ T cells can be induced by activation. Co-culture of naïve CD4+ T cells with HLA-B272-expressing cells preferentially promotes the survival of KIR3DL2+ CD4+ T cells and promotes a Th17 (and Th1) transcriptional profile.  SpA KIR3DL2+ CD4+ T cells are enriched for production of IL-17 and for dual production of IL-17 and IFNγ, consistent with the theory that AS is a Th17 or a Th17/1 driven disease.


Disclosure:

A. Ridley,
None;

I. Wong-Baeza,
None;

H. Hatano,
None;

J. Shaw,
None;

H. Al-Mossawi,
None;

P. Bowness,
None;

S. Kollnberger,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hla-b27-and-kir3dl2-interactions-promote-the-differentiation-and-survival-of-proinflammatory-t-cells-in-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology